Source comparison
Melanotan-2 Dosage Appetite Suppression 2026: Clinical vs Research Context
0.1–0.25mg daily Minimal appetite reduction; threshold MC4R activation Very low. No visible darkening in most users 20–30% during first week Initial sensitivity testing; pediatric research contexts Subtherapeutic for most adults; useful for assessing individua
This comparison does not assign a generated winner or score.
- 0.1–0.25mg daily
- Minimal appetite reduction; threshold MC4R activation
- Very low. No visible darkening in most users
- 20–30% during first week
- Initial sensitivity testing; pediatric research contexts
- Subtherapeutic for most adults; useful for assessing individual receptor sensitivity before escalation
- 0.25–0.5mg daily
- Moderate appetite suppression; 15–25% reduction in ad libitum caloric intake
- Low. Slight darkening of existing moles and freckles after 3–4 weeks
- 40–50% during first week, resolves by day 7–10
- Appetite-focused protocols; patients avoiding pigmentation
- Optimal starting range for appetite suppression without cosmetic effects in most users
- 0.5–1.0mg daily
- Pronounced appetite suppression; 25–40% reduction in meal size and snacking frequency
- Moderate. Visible skin darkening after 10–15mg cumulative dose
- 50–60% during first week; may persist at higher end of range
- Dual cosmetic and metabolic intent; tanning protocols with secondary appetite benefit
- Effective for satiety but approaches threshold where melanogenesis becomes unavoidable; consider dose reduction if pigmentation is unwanted
- 1.0–2.0mg daily
- Maximal MC4R-mediated appetite suppression; diminishing returns above 1.5mg
- High. Rapid and pronounced darkening within 7–10 days
- 60–70%; nausea often persists beyond first week at this range
- Cosmetic tanning protocols; research investigating maximum tolerated dose
- Appetite suppression does not scale linearly above 1.0mg. Higher doses primarily increase off-target effects and melanogenesis
- Real Peptides supplies research-grade Melanotan-2 synthesised with exact amino-acid sequencing and verified purity. Every batch undergoes HPLC and mass spectrometry analysis to confirm molecular weight and detect impurities. Critical quality controls that determine whether the peptide produces the intended melanocortin receptor activation or unpredictable off-target effects. Inconsistent synthesis is the primary reason some users report appetite suppression at 0.25mg while others see no effect below 1.0mg. Sequence errors or incomplete cyclisation during peptide assembly create analogs with altered receptor binding affinity.